PROFILE-V MEDTOXSCAN DRUGS OF ABUSE TEST SYSTEM AND 12 DRUGS TEST SYSTEM

K100023 · Medtox Diagnostics, Inc. · DJG · Apr 5, 2010 · Clinical Toxicology

Device Facts

• Record ID: K100023
• Device Name: PROFILE-V MEDTOXSCAN DRUGS OF ABUSE TEST SYSTEM AND 12 DRUGS TEST SYSTEM
• Applicant: Medtox Diagnostics, Inc.
• Product Code: DJG · Clinical Toxicology
• Decision Date: Apr 5, 2010
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 862.3650
• Device Class: Class 2

Indications for Use

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System consists of the PROFILE®-V MEDTOXScan® Test Devices and the MEDTOXScan® Reader. The PROFILE®-V MEDTOX Scan® Test Devices are one-step immunochromatographic tests for the rapid, qualitative detection of one or more of the following in human urine: Amphetamines, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Methamphetamine, Opiates, Oxycodone, Phencyclidine, Propoxyphene, THC (Cannabinoids), and Tricyclic Antidepressants or their metabolites. The PROFILE®-V MEDTOXScan® Test Devices can only be used with the MEDTOXScan® Reader. The MEDTOX Scan® Reader is an instrument used to interpret and report the results of the PROFILE®-V MEDTOXScan® Test Device. PROFILE®-V MEDTOXScan® Test Devices cannot be visually read. The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System is for in vitro diagnostic use and is intended for professional use only. It is not intended for use in point-of-care settings.

Device Story

System comprises single-use immunochromatographic test cassettes and MEDTOXScan® Reader. Urine sample applied to cassette; membrane strip contains drug-conjugates and antibody-colloidal gold. Reader uses contact imaging sensor (CIS) to scan test lines; software interprets line presence/absence to determine qualitative positive/negative results. Used by professionals in clinical settings; not for point-of-care. Output provided via LCD screen or printout. Provides preliminary analytical results; requires confirmatory testing (GC/MS, HPLC, or LC/MS/MS) for clinical decision-making. Benefits include rapid screening for multiple drug classes.

Clinical Evidence

No clinical studies performed. Performance validated via method comparison study using 172 unaltered clinical urine samples compared against GC/MS or LC/MS/MS reference methods. Precision evaluated with 45 replicates per concentration level across 3 readers and 8 operators. Analytical specificity, cross-reactivity, and interference (pH, specific gravity, common drugs) were assessed via bench testing.

Technological Characteristics

Single-use immunochromatographic lateral flow test cassettes; gold-conjugated reagents. Reader utilizes contact imaging sensor (CIS) for optical signal detection. System includes QC and cleaning cassettes for sensor maintenance. Software-based interpretation of line intensity. Standalone instrument with display and printout capability.

Indications for Use

Indicated for professional, in vitro diagnostic use in clinical settings (not point-of-care) for the rapid, qualitative detection of drugs of abuse or their metabolites in human urine. Target analytes include Amphetamines, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Methadone, Methamphetamine, Opiates, Oxycodone, Phencyclidine, Propoxyphene, THC, and Tricyclic Antidepressants. Results are preliminary; confirmatory testing via GC/MS, HPLC, or LC/MS/MS is required.

Regulatory Classification

Identification

An opiate test system is a device intended to measure any of the addictive narcotic pain-relieving opiate drugs in blood, serum, urine, gastric contents, and saliva. An opiate is any natural or synthetic drug that has morphine-like pharmocological actions. The opiates include drugs such as morphine, morphine glucoronide, heroin, codeine, nalorphine, and meperedine. Measurements obtained by this device are used in the diagnosis and treatment of opiate use or overdose and in monitoring the levels of opiate administration to ensure appropriate therapy.

Special Controls

*Classification.* Class II (special controls). An opiate test system is not exempt if it is intended for any use other than employment or insurance testing or is intended for Federal drug testing programs. The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 862.9, provided the test system is intended for employment and insurance testing and includes a statement in the labeling that the device is intended solely for use in employment and insurance testing, and does not include devices intended for Federal drug testing programs (*e.g.,* programs run by the Substance Abuse and Mental Health Services Administration (SAMHSA), the Department of Transportation (DOT), and the U.S. military).

Predicate Devices

• PROFILE®-V MEDTOXScan® Drugs of Abuse Test System (K091454)

Submission Summary (Full Text)

{0}

1

# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY TEMPLATE

A. 510(k) Number:
k100023

B. Purpose for Submission:
Addition of 2 new drugs of abuse tests (buprenorphine and opiates 2000) to an already cleared reader (MEDTOXScan® Reader, k080635). Amphetamines, Barbiturates, Benzodiazepines, Cocaine, Methadone, Methamphetamine, Opiates 100, Oxycodone, Phencyclidine, Propoxyphene, THC and Tricyclics antidepressants assays were previously cleared on the reader.

C. Measurand:
Buprenorphine and Opiates 2000

D. Type of Test:
Qualitative immunochromatographic test for drugs of abuse in urine performed on a reader.

E. Applicant:
Medtox Diagnostics, Inc.

F. Proprietary and Established Names:
PROFILE®-V MEDTOXScan®

G. Regulatory Information:
| Product Code | Classification | Regulation Section | Panel |
| --- | --- | --- | --- |
| DJG – Opiate Test System | II | 862.3650 | 91- Toxicology |

H. Intended Use:
1. Intended use(s):
See indications for use below.

{1}

2

2. Indication(s) for use:

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System consists of the PROFILE®-V MEDTOXScan® Test Devices and the MEDTOXScan® Reader. The PROFILE®-V MEDTOX Scan® Test Devices are one-step immunochromatographic tests for the rapid, qualitative detection of one or more of the following in human urine: Amphetamines, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine, Methadone, Methamphetamine, Opiates, Oxycodone, Phencyclidine, Propoxyphene, THC (Cannabinoids), and Tricyclic Antidepressants or their metabolites. The PROFILE®-V MEDTOXScan® Test Devices can only be used with the MEDTOXScan® Reader. The MEDTOX Scan® Reader is an instrument used to interpret and report the results of the PROFILE®-V MEDTOXScan® Test Device. PROFILE®-V MEDTOXScan® Test Devices cannot be visually read. The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System is for in vitro diagnostic use and is intended for professional use only. It is not intended for use in point-of-care settings. The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System detects drug classes at the following cutoff concentrations:

| AMP Amphetamine (d-Amphetamine) | 500 ng/mL | OPI Opiates (Morphine) | 100 ng/mL or 2000 ng/mL |
| --- | --- | --- | --- |
| BAR Barbiturates (Butalbital) | 200 ng/mL | OXY Oxycodone (Oxycodone) | 100 ng/mL |
| BUP Buprenorphine (Nordiazepam) | 10 ng/mL | PCP Phencyclidine (Phencyclidine) | 25 ng/mL |
| COC Cocaine (Benzoylecgonine) | 150 mg/mL | PPX Propoxyphene (Norpropoxyphene) | 300 ng/mL |
| MAMP Methamphetamine (d-Methamphetamine) | 500 ng/mL | THC (Cannabinoids 11-nor-9-carboxy-r9-THC) | 50 ng/mL |
| MTD Methadone (Methadone) | 200 ng/mL | TCA Tricyclic Antidepressants (Desipramine) | 300 ng/mL |

Configurations of the PROFILE®-V MEDTOXScan® Test Devices may consist of any combination of the above listed and previously cleared drug. Test Devices will have an opiate cutoff of either 100 ng/mL or 2000 ng/mL. Refer to specific product labeling for the combination of drug tests included on that test device.

The PROFILE®-V MEDTOXScan® DRUGS OF ABUSE TEST SYSTEM PROVIDES ONLY A PRELIMINARY ANALYTICAL TEST RESULT. A MORE SPECIFIC ALTERNATE CHEMICAL METHOD MUST BE USED IN ORDER TO OBTAIN A CONFIRMED ANALYTICAL RESULT. GAS CHROMATOGRAPHY / MASS SPECTROMETRY (GC/MS), HIGH

{2}

PERFORMANCE LIQUID CHROMATOGRAPHY (HPLC) OR LIQUID CHROMATOGRAPHY / TANDEM MASS SPECTROMETRY (LC/MS/MS) ARE THE PREFERRED CONFIRMATORY METHODS. CLINICAL CONSIDERATION AND PROFESSIONAL JUDGMENT SHOULD BE APPLIED TO ANY DRUG OF ABUSE TEST RESULT, PARTICULARLY WHEN PRELIMINARY POSITIVE RESULTS ARE OBTAINED.

The MEDTOXScan® Reader includes a Positive QC Test Device, a Negative QC Test Device and a Cleaning Cassette. The MEDTOXScan® Positive and Negative QC Test Devices are intended to detect errors associated with the MEDTOXScan® Reader and a contaminated contact imaging sensor (CIS), and to verify that the CIS cleaning procedure using the MEDTOXScan® Cleaning Cassette effectively removed any contamination.

3. Special conditions for use statement(s):

The device is for in vitro diagnostic prescription use.

The assay is not designated for use in the point-of-care settings.

The PROFILE®-V MEDTOXScan® Tes devices cannot be visually read.

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmation analytical result. Gas chromatography/mass spectrometry (GC/MS), high performance liquid chromatography (HPLC) or liquid chromatography/tandem mass spectrometry (LC/MS/MS) are the preferred confirmatory methods. Clinical consideration and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are obtained.

The positive and negative QC test devices should not be used to replace performing QC using external liquid quality control materials.

4. Special instrument requirements:

PROFILE®-V MEDTOXScan®

I. Device Description:

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System kit contains PROFILE®-V MEDTOXScan® Test Devices for use with the MEDTOXScan® Reader.

3

{3}

- Each test device has all the reagents necessary to test one urine sample for one or more drugs simultaneously on the MEDTOXScan® Reader.
- Each test device holds one or more test strips composed of a membrane strip coated with drug conjugate and a pad coated with antibody-colloidal gold in a protein matrix.

Kit Contents:
1. Twenty-five (25) test devices in individual foil packages
2. Twenty-five (25) disposable pipette tips
3. One Quick Reference guide

MEDTOXScan® Reader Contents:
1. Positive and Negative QC Test Devices
2. Cleaning Cassette
3. MiniPet pipettor
4. Quick Set Up guide
5. User Manual

## J. Substantial Equivalence Information:

1. Predicate device name(s):
PROFILE®-V MEDTOXScan®

2. Predicate 510(k) number(s):
k091454

3. Comparison with predicate:
The device and the predicate device have the same intended use and test the same sample type (urine). The similarities and differences are presented below.

| Item
Intended use | Similarities/Differences | |
| --- | --- | --- |
| | Device
Determines qualitative positive or negative result from drug of abuse immunoassay screens. | Predicate
Same |
| System Procedure Measurement Method
Output | Sample is added to a single use test cassette, which is then read by instrument. Instrument is designed to read multiple single use test cassettes, one at a time. Scans the single-use test cassette with contact imaging sensor (CIS) to detect a single Outputs “positive,” “negative,” and “invalid” test results on | Same |

{4}

5

| paper printout or LCD screen; stores and uploads results. | | |
| --- | --- | --- |
| Analytes | Amphetamines, Barbiturates, Benzodiazepines, Buprenorphine, Cocaine Methadone, Methamphetamine, Opiates, Oxycodone, Phencyclidine, Propoxyphene, THC (Cannabinoids) and Tricyclic Antidepressants | Amphetamines, Barbiturates, Benzodiazepines, Cocaine Methadone, Methamphetamine, Opiates, Oxycodone, Phencyclidine, Propoxyphene, THC (Cannabinoids) and Tricyclic Antidepressants |

K. Standard/Guidance Document Referenced (if applicable):

None were referenced

L. Test Principle:

The PROFILE®-V MEDTOXScan® Drugs of Abuse Test System includes a competitive, membrane-based immunochromatographic PROFILE®-V MEDTOXScan® Test Device and the MEDTOXScan® Reader.

Antibody-Colloidal Gold: Mouse monoclonal antibodies bind to the drug being tested.

Drug-Conjugates: Each drug to be tested was individually conjugated to bovine serum albumin (BSA) or IgG. Each drug conjugate is immobilized on a test line at a designated position on the membrane strip.

Control Line: Each test strip has anti-mouse antibody immobilized at the Control (C) position of the membrane strip. The anti-mouse antibody will bind excess antibody-colloidal gold, indicating that the reagents are working properly. When the urine sample is placed in the sample well of a test strip, the dried antibody-colloidal gold under the sample pad dissolves and the urine wicks up the white strips carrying the reddish-purple antibody-colloidal gold with it.

The MEDTOXScan® Reader scans the test device and utilizes a contact imaging sensor (CIS) to capture relative line intensities. Software algorithms and barcodes are used to identify the test device, the drug tests associated with the test device and whether the presence or absence of a line is associated with a negative or positive result, respectively.

{5}

6

# Negative Samples

When no drug(s) is present in the urine sample, the reddish purple antibody-colloidal gold solutions migrate along the strip and bind to the respective drug conjugate(s) immobilized on the membrane. Each strip has up to 4 drug test lines. Labeled T1-T4. The binding of the antibody-colloidal gold to the drug conjugate generates a line at the corresponding test position on the strip. The MEDTOXScan® Reader will scan each test position and if a line is detected it will return “NEG” on the display screen (or print out) next to the abbreviation for the drug test, indicating a negative result.

# Positive Samples

When drug(s) is present in the urine sample the antibody-colloidal gold binds to the drug(s) before it migrates along the strip. When the antibody-colloidal gold binds to the drug(s) in the urine, it cannot bind to the drug conjugate immobilized on the membrane and no line is generated at the drug specific position in the result window. The MEDTOXScan® Reader will scan each test position and if no line is detected it will return “POS” on the display screen (or print out) next to the abbreviation for the drug test, indicating a preliminary positive result.

# Control Line (Valid or Invalid results)

Each test strip has an internal procedural control. A line must form at the Control (C) position in the result window to indicate that sufficient sample was applied and that the reagents are migrating properly. If a Control line does not form, the test is invalid. The MEDTOXScan® Reader scans each control line and returns “VALID” to the right of the drug test result to confirm that the control line was detected. If no control line is detected it will return “INVALID” on the display screen (or print out) next to the abbreviation for the invalid drug test, and no result will be given for that drug test.

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

Urine stock solutions were prepared for each test compound by spiking standard solution of known concentrations into negative pool urine. Each stock solution concentration was confirmed by GC/MS or LC/MS/MS. The stock solution was serially diluted into negative urine to obtain concentrations of 50%, 75%, 125% and 150% of the cutoff. The prepared sample concentrations were confirmed by GC/MS or LC/MS/MS. A total of 45 results (3 readers x 3 aliquots for 5 days and one strip lot) were obtained for each level. Testing was rotate between 8 operators. The results are presented in the tables below:

{6}

| Buprenorphine Cutoff=10 ng/mL | | | | |
| --- | --- | --- | --- | --- |
| Conc. (ng/mL) | % of Cutoff | Number Tested | Positive | Negative |
| Negative | Negative | 45 | 0 | 45 |
| 5 | 50% | 45 | 0 | 45 |
| 7.5 | 75% | 45 | 15 | 30 |
| 12.5 | 125% | 45 | 45 | 0 |
| 15 | 150% | 45 | 45 | 0 |
| Opiate (Morphine) Cutoff = 2000 ng/mL | | | | |
| --- | --- | --- | --- | --- |
| Conc. (ng/mL) | % of Cutoff | Number Tested | Positive | Negative |
| Negative | Negative | 45 | 0 | 45 |
| 1000 | 50% | 45 | 0 | 45 |
| 1500 | 75% | 45 | 14 | 31 |
| 2500 | 125% | 45 | 45 | 0 |
| 3000 | 150% | 45 | 45 | 0 |

b. Linearity/assay reportable range:

Not applicable. This is a qualitative test.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Profile V quality control materials were previously cleared and are sold separately. The sponsor specifies the quality control product in the "materials required but not provided" section of the labeling.

No calibrators are required. The device is calibrated during the manufacturing process.

d. Detection limit:

Analytical performance of the device around the cutoff is described in the precision section 1.a above.

e. Analytical specificity:

Cross-reactivity was established by spiking various concentrations of similarly structured drug compounds into drug-free urine. Results are expressed as a minimum concentration of metabolite or compound required to produce a response approximately equivalent to the cutoff concentration of the assay. The percent cross re-activities of those compounds are presented below:

{7}

| Opiates (OPI) (Morphine) 2000 ng/mL | | |
| --- | --- | --- |
| Compound | Result | % Cross Reactive |
| Codeine | Positive at 900 ng/mL | 222% |
| Diacetylmorphine | Positive at 2500 ng/mL | 80% |
| Dihydrocodeine | Positive at 3800 ng/mL | 53% |
| Ethylmorphine | Positive at 600 ng/mL | 333% |
| Hydrocodone | Positive at 1400 ng/mL | 143% |
| Hydromorphine | Positive at 1900 ng/mL | 105% |
| Levorphanol | Positive at 5000 ng/mL | 40% |
| 6-Monoacetylmorphine | Positive at 3800 ng/mL | 53% |
| Morphine 3-β-D-Glucuronide | Positive at 5000 ng/mL | 40% |
| Morphine 6-β-D-Glucuronide | Positive at 6000 ng/mL | 33% |
| Norcodeine | Positive at 40,000 ng/mL | 5% |
| Thebaine | Positive at 2500 ng/mL | 80% |
| Apomorphine | Negative at 100,000 ng/mL | None Detected |
| Nalorphine | Negative at 100,000 ng/mL | None Detected |
| Naloxone | Negative at 100,000 ng/mL | None Detected |
| Naltrexone | Negative at 100,000 ng/mL | None Detected |
| Oxycodone | Negative at 100,000 ng/mL | None Detected |
| Oxymorphone | Negative at 100,000 ng/mL | None Detected |

{8}

Non Cross-reactive endogenous compounds

The following compounds were evaluated for reactivity with the Profile V device at 100 ug/mL (albumin was evaluated at 20 mg/mL and bilirubin was evaluated at 200 ug/mL). Samples were evaluated in triplicate by in-house operators. None of the listed compounds affected the expected results.

| Acetaldehyde | Creatinine | Hemoglobin, Human |
| --- | --- | --- |
| Acetone | Epinephrine | Sodium Chloride |
| Albumin, Human | b-Estradiol | Tetrahydrocortisone |
| Bilirubin | Estriol | D, l-Thyroxine |
| Cholesterol | Glucose Std. | Uric Acid |

Unrelated Compounds, Prescription and Over-the-Counter Medication

Common compounds were evaluated for reactivity at 100 ug/mL. Samples were evaluated in triplicate by in-house operators. The list of compounds tested can be found in the package insert.

Common Drugs

Drug free urine samples were spiked with the Profile V targeted drugs to the concentrations of 50% and 125% of the cutoff concentrations. An amount of 100,000 ng/mL of each common drug was added to the preparation and assayed. Evaluations were performed in triplicate by in-house operators. None of the common drugs listed affected the expected results.

| Acetylsalicylic Acid | Chorpheniramine | Morphine – OPI, OXY |
| --- | --- | --- |
| Acetaminophen | Cocaine | Phenobarbital |
| Brompheniramine Maleate | Dextromethorphan | Phenytoin |
| Caffeine | Doxylamine | d-Pseudoephedrine |
| Carbamazepine | Ibuprofen | Salicylic Acid |

There is the possibility that other substances and/or factors not listed above may interfere with the test and cause false results.

pH and Specific Gravity

To test for possible positive and/or negative interference drug free urine was divided into three aliquots and adjusted to the following pH

{9}

concentrations 4.0, 7.0, and 9.0. Each of these samples was spiked to 50% of the cutoff and 125% of the cutoff for each drug. Each sample was assayed in triplicate. No negative interference due to pH was observed.

To test for possible positive and/or negative interference from specific gravity drug free urine samples having specific gravity from 1.003, 1.015 and 1.030 were used. Each of these samples were divided into two aliquots for each drug and spiked to 50% of the cutoff and 125% of the cutoff. No negative interference due to specific gravity was observed.

f. Assay cut-off:

Characterization of how the device performs around the claimed cutoff concentration appears in the precision section 1.a., above.

2. Comparison studies:

a. Method comparison with predicate device:

Performance was evaluated by 2 operators who tested a total of 172 unaltered clinical samples, 88 samples for OPI and 84 samples for BUP. The samples were compared to the GC/MS or LC/MS/MS. The results are presented in the table below:

| Durg ng/mL | Candidate Device Results | Negative | Less than half the cutoff concentration by GC/MS or LC/MS/MS | Near Cutoff Negative (Between 50% below the cutoff and the cutoff concentration) | Near Cutoff Positive (Between the cutoff and 50% above the cutoff concentration) | High Positive (greater than 50% above the cutoff concentration) |
| --- | --- | --- | --- | --- | --- | --- |
| BUP (10) | Positive | 0 | 0 | 0 | 4 | 36 |
| | Negative | 40 | 0 | 4 | 0 | 0 |
| OPI (2000) | Positive | 0 | 0 | 1 | 4 | 36 |
| | Negative | 40 | 4 | 3 | 0 | 0 |

The summary of discordant results is listed in the table below:

| Assay | Cutoff Value (ng/mL) | Profile V Assay Pos/Neg | GC/MS or LC/MS/MS value (ng/mL) |
| --- | --- | --- | --- |
| OPI | 2000 | Positive | Morphine at 1375 ng/mL |

{10}

b. Matrix comparison:
Not applicable. The assay is intended for use with urine samples only.

3. Clinical studies:
a. Clinical Sensitivity:
Not applicable
b. Clinical specificity:
Not applicable
c. Other clinical supportive data (when a. and b. are not applicable):
Not applicable

4. Clinical cut-off:
Not applicable

5. Expected values/Reference range:
Not applicable

N. Proposed Labeling:
The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

O. Conclusion:
The submitted information in this premarket notification is complete and supports a substantial equivalence decision.